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Abstract
The Global Program to Eliminate Lymphatic Filariasis (LF) has a target date of 2020. This program is progressing well in many
countries. However, progress has been slow in some countries, and others have not yet started their mass drug
administration (MDA) programs. Acceleration is needed. We studied how increasing MDA frequency from once to twice per
year would affect program duration and costs by using computer simulation modeling and cost projections. We used the
LYMFASIM simulation model to estimate how many annual or semiannual MDA rounds would be required to eliminate LF
for Indian and West African scenarios with varied pre-control endemicity and coverage levels. Results were used to estimate
total program costs assuming a target population of 100,000 eligibles, a 3% discount rate, and not counting the costs of
donated drugs. A sensitivity analysis was done to investigate the robustness of these results with varied assumptions for key
parameters. Model predictions suggested that semiannual MDA will require the same number of MDA rounds to achieve LF
elimination as annual MDA in most scenarios. Thus semiannual MDA programs should achieve this goal in half of the time
required for annual programs. Due to efficiency gains, total program costs for semiannual MDA programs are projected to
be lower than those for annual MDA programs in most scenarios. A sensitivity analysis showed that this conclusion is robust.
Semiannual MDA is likely to shorten the time and lower the cost required for LF elimination in countries where it can be
implemented. This strategy may improve prospects for global elimination of LF by the target year 2020.
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Introduction
The Global Program to Eliminate Lymphatic Filariasis
(GPELF) was launched in 2000 with the aim of eliminating
lymphatic filariasis (LF) as a public health problem by 2020 [1].
The recommended strategy is to treat entire at-risk populations
annually with a single dose of ivermectin and albendazole
(IVM+ALB) in sub-Sahara Africa or with diethylcarbamazine
and albendazole (DEC+ALB) in other regions for a minimum of 5
years [2]. Mapping studies suggest that mass drug administration
(MDA) is needed in 72 endemic countries [3].
As indicated in the GPELF 2010 progress report, progress
toward LF elimination varies widely between countries [3]. Some
countries started their MDA programs early and may have already
interrupted LF transmission, while other countries lag behind [3].
Nineteen countries had not yet started MDA, and geographical
coverage was incomplete in 24 others. Reasons cited for slow
progress in some areas included major logistic challenges, political
instability, conflict, and co-endemicity with Loa loa [4]. Also, results
from ongoing MDA programs have sometimes been disappoint-
ing. Sentinel site data collected after 5 years of annual MDA show
that microfilaria (mf) prevalence had dropped to 0% in about two-
thirds of sentinel sites sampled. However, mf rates had decreased
by less than 50% in 10% of the sites sampled [4].
With the goal of LF elimination by 2020 in mind, it is now
important and timely to study whether elimination programs can
be accelerated. A straightforward option would be to increase the
frequency of MDA from once per year (annual) to twice per year
(semiannual). While increasing MDA frequency might be expected
to shorten the time required for elimination, the magnitude of this
effect is uncertain. Only one study directly compared the impact of
annual and semiannual MDA and this was for brugian filariasis:
semiannual MDA with DEC alone caused a more rapid decline in
mf prevalence than annual treatment. However, the duration of
this study was too short to support conclusions regarding
elimination [5]. Results from other studies of semiannual MDA
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are difficult to interpret, because they did not provide results from
a control area with annual MDA [6,7,8].
For decision-making, it is also important to consider how costs
per year and overall costs for LF elimination programs are likely to
change if MDA frequency is increased. Of course, costs per year
will increase, but they will not necessarily double, and the
cumulative cost for the entire program may even decline. The
costs of twice yearly MDA have not been formally studied for LF
or other neglected tropical diseases. However, they can be
projected from detailed cost data by activity and cost item that
are available for yearly MDA for LF and soil-transmitted
helminthiasis [9,10,11,12].
We have used the well-established simulation model LYMFA-
SIM to estimate the number of treatment rounds and duration of
MDA programs that would be needed to eliminate LF with annual
and semiannual MDA in different settings. Simulations were
performed for typical endemic areas in West Africa (with
IVM+ALB treatment and Anopheles transmission) and in India
(with DEC+ALB treatment and Culex transmission) with different
pre-control endemicity levels and MDA coverage rates. In
addition, we have compared projected costs of annual or
semiannual MDA, both per year and for the total required
duration of LF elimination programs.
Methods
Estimating the required duration of annual and
semiannual MDA programs
The LYMFASIM simulation model. The LYMFASIM
model describes the transmission of Wuchereria bancrofti parasites
in a dynamic human population, to predict time trends in infection
indicators and the effects of control programs. The LYMFASIM
model employs the technique of stochastic microsimulation [13],
to allow inclusion of chance processes and variation in important
human characteristics and behaviors. The mathematical back-
ground of the model was described in detail by Plaisier et al. [14].
Here we provide a brief description.
The model simulates a closed population, consisting of a
discrete number of individuals. The population composition
changes over time due to birth and death of individuals. The
history of infection and disease is simulated at the level of the
individual human, taking account of individual variation in
exposure to mosquito bites (age-related or random), life span,
immune responsiveness to infection, compliance with MDA
programs, and responsiveness to treatment. Worms in humans
are also simulated individually, allowances made for separate sexes
and variable life spans. Mature female worms produce mf during
their reproductive lifespan at certain rates when there are male
worms present in the human body. Because of all these factors,
worm loads and mf intensity vary between human individuals, as
well as their contribution to the average force of infection working
on the population. In calculating the latter, the model considers
the vector species-specific non-linear relationship between mf
intensity in human blood and the average number of mf engorged
by biting mosquitoes.
The primary outcomes of the model are predicted trends in the
mf prevalence rate and mean mf intensity in the population. These
outcomes are based on mf counts for all individuals in the
population, while taking account of test characteristics that
determine sampling variation and the possibility of false-negative
test results. This makes simulation outcomes directly comparable
to field data. For the present study, we assumed that mf counts
were done by microscopic examination of a 20-ml or 60-ml thick
smear of night finger-prick blood.
Modeling specific endemic regions. We used previously
developed LYMFASIM model variants for India and West Africa.
The India model describes the epidemiology of bancroftian
filariasis in India which is transmitted by Culex quinquefasciatus,
and it was tested against longitudinal data from Pondicherry, India
[15]. The West Africa model describes the epidemiology in
African regions where Anopheles-species are the only vectors of LF.
This model was validated against cross-sectional data [16]. We
refer to the original publications for details about model parameter
values and the procedures used for parameter estimation and
validation.
Table 1 lists values for key parameters for the India and West
Africa model variants. Many parameters were assumed to have the
same value in both models, such as the parameters describing the
parasite life cycle, age-variation in exposure, and variability in mf
counts. Assumptions about immunity differ between the two
model variants, to explain the different epidemiological patterns.
In Pondicherry, India, mf prevalence and mf intensity declined in
the oldest age groups, and a form of acquired immunity was
incorporated into the model. Here, we assume that immunity,
triggered by incoming L3 larvae, reduces the probability for
incoming L3 larvae to develop successfully into adult worms. Since
such a decline in mf prevalence is unusual in Africa and mf
prevalence rates in this region tend to be higher than those in
India [17], the West Africa model does not include acquired
immunity.
The relationship between human blood mf density and
mosquito parasite uptake also differs between the two models,
reflecting known differences between the vector species. The India
model for Culex quinquefasciatus assumes ‘limitation’ in this
relationship: ‘‘L3 yield’’ in mosquitoes (i.e. the number of L3
developing in mosquitoes per mf in the human blood) declines
monotonically with increasing mf density in the human blood and
saturation occurs at high mf densities. The West Africa model
assumes ‘facilitation’: the L3 yield initially increases with mf
density in human blood, although limitation still causes saturation
at higher mf densities [16].
The West Africa model assumes relatively strong inter-
individual variation in exposure to mosquito bites (indicated by
the low value for the shape parameter of the gamma distribution in
the West Africa model), to capture the variation between people in
mf density in the human blood. The India model assumes less
Author Summary
The Global Program to Eliminate Lymphatic Filariasis (LF)
employs annual mass drug administration (MDA) of
antifilarial drugs to reduce infection rates in populations
and interrupt transmission. While this program is working
well in many countries, progress has been slow in others,
and some countries have not yet started MDA programs.
We used computer simulation modeling and cost projec-
tions to study how increasing MDA frequency from once
to twice per year would affect program duration and costs.
Our results suggest that semiannual MDA is likely to
reduce the time required to eliminate LF by 50% and
reduce total program costs (excluding the cost of donated
drugs) in most situations. For these and other reasons, we
expect semiannual MDA to be superior to annual MDA in
most endemic settings. Semiannual MDA should be
considered as a means of accelerating LF elimination in
areas where it can be implemented, because this may
improve prospects for global elimination of LF by the
target year 2020.
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variability in exposure, because the variability in human mf
density is partly attributed to acquired immunity and the
associated individual differences in immune responsiveness.
Further, the monthly biting rate (mbr, defined as average number
of mosquito bites per adult person per month) is known to vary
between communities, and we considered different values as
explained below.
Simulated scenarios and MDA assumptions. We per-
formed simulation experiments to estimate the duration of MDA
required to achieve LF elimination using different values for key
parameters in the Indian and West African models. Mbr values
were chosen to simulate communities with low, intermediate or
high pre-control mf prevalence levels that are encountered in these
regions. The simulated pre-treatment mf prevalence levels (based
on 60 mL blood smears) were 7.7%, 11.5% and 15% for India and
12.5%, 20% and 27.5% for West Africa. Corresponding values for
20 mL blood smears would be approximately 5%, 7.5% and 10%
for India and 9%, 14% and 20% for West Africa.
For each setting, we simulated a range of treatment scenarios
that varied with respect to simulated treatment regimens
(DEC+ALB or IVM+ALB), frequency of treatment (annual or 6-
monthly), treatment coverage (55%, 70% or 85% of the total
population; constant over time), and the number of treatment
rounds (1, 2, …, 20 rounds). Compliance with offered treatment
was simulated as a partially systematic process. That is to say, it is
neither completely random (where each person has the same
chance to get treated in each round) nor completely systematic
(where all individuals either take all or none of the treatments), but
somewhere in between. The simulated proportion of systematic
non-compliers (i.e. those who never take treatment) for a given
number of treatment rounds is not fixed; it depends on overall
treatment coverage levels; the proportion of systematic non-
compliers in the total population increases when the overall
coverage declines, and vice versa. This mechanism fairly
represented the attendance pattern of a mass treatment program
for onchocerciasis in Asubende, Ghana [18].
Baseline treatment efficacy assumptions were based on expert
opinion and ultrasound studies [19,20,21], as justified elsewhere
[22]. A single treatment with DEC+ALB was assumed to kill 70%
of mf and to kill or permanently sterilize 65% of adult worms.
Similarly, a single treatment with IVM+ALB was assumed to kill
100% of mf and to kill or permanently sterilize 35% of adult
worms. These treatment effects were assumed to occur just after
treatment. Further, we assumed that there is no inter-individual
variation in treatment effects and that the treatment efficacy is the
same in all treatment rounds.
Estimating required program durations. To calculate the
probability of LF elimination for a certain setting and treatment
scenario, we performed repeated simulations (n = 1000), all with
the exact same assumptions. We recorded for each run whether
elimination was reached (defined as mf prevalence ,0.1%,
measured 60 years after the first MDA to allow for slow extinction
Table 1. Values of LYMFASIM parameters in models for India and West Africa.
Parameter value
Description India West Africa
Average number of mosquito bites/adult person/month, for areas with low,
intermediate and high pre-control Mf prevalence
1600,1950,2700 430, 485, 650
Exposure at birth, fraction of maximum exposurea 0.26 0
Age at which exposure reaches maximuma 19.1 years 20.0 years
Shape parameter for c distribution describing individual variation in
exposure (mean = 1; a higher value indicates less variability)
1.13 0.26
Function that specifies the number of L3-larvae developing in mosquitoes after a single
blood meal as a function of human mf density in 20 ml of blood (m)
(0.089 m)/(1+6.6 m) 1.67(1-exp(-(0.027 m)1.51)
Success ratio: the fraction of incoming L3 larvae that survive and develop into
mature adult worms.
1.0361023 8.861023
Fraction of L3 larvae, from 1 blood meal, released by a mosquito when it bites 0.1 0.1
Mean life span of parasites in human host 10.2 years 10.0 years
Shape parameter for the Weibull distribution that describes variation in parasite life span 2.0 2.0
Duration of immature stage of parasite in human host 8 months 8 months
Fraction of microfilariae surviving per month 0.9 0.9
Number of Mf produced/female parasite/month/20 ml of peripheral blood 0.61 0.58
Scale parameter for sigmoid function relating strength of anti-L3 immunity to experience
of infection by L3
5.8961025 n.a.
Shape parameter for c distribution describing individual variation in ability to develop
anti-L3 immunity
1.07 n.a.
Duration of immunological memory for anti-L3 immunity 9.6 months n.a.
Clumping factor for the negative binomial distribution describing variation in mf-counts in
20 mL blood smears from an individual with given mf density. Between brackets: idem,
for 60 mL blood smears
0.345 (1.035) 0.33 (0.99)
The table lists parameters related to transmission and parasite development, for which the values may vary between the models. See original publications for a full
justification of the parameter values [15,16].
n.a. = not applicable.
aExposure increases with age until a maximum is achieved at a certain age; exposure remains at its maximum level thereafter.
doi:10.1371/journal.pntd.0001984.t001
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of the parasite population when mf prevalence was brought below
its breakpoint level). The elimination probability was defined as
the percentage of runs that reached this outcome. The required
number of MDA rounds for elimination was estimated as the
lowest number of MDA rounds that resulted in a $99%
probability of elimination. For annual MDA programs, the
estimated required number of MDA rounds equals the duration
of MDA in years. For semiannual MDA programs, the duration of
MDA in years equals the number of MDA rounds divided by 2.
Estimating the costs of annual and semiannual MDA
We estimated the costs of MDA for LF programs with annual
and semiannual treatment from the perspective of the endemic
country government. The cost analysis covers financial and
economic costs. The financial costs are the costs of all inputs
purchased in cash for MDA, including purchased MDA drugs,
materials and supplies, ministry of health personnel salaries, and
per diem payments for community drug distributors [11].
Economic costs also include the costs of donated drugs for MDA
(India: albendazole; Burkina Faso: ivermectin, albendazole). Costs
were calculated for a target population of 100,000 eligible persons
in three steps.
Step 1. Estimate the cost per treatment round for annual
MDA from published data. For India, we based our
calculations on published data on the total cost per treatment
round as estimated by Ramaiah and Das [23]. The total costs as
published were measured in 1996 and included the cost of
purchased DEC (50 mg tablets). The India program relied on
government health workers for drug distribution and did not use
volunteers. This study did not include central government costs for
planning. It was carried out at the district level and it measured
personnel time at the district level.
For West Africa we used recently published data from Burkina
Faso on total costs of MDA (measured in 2002) excluding the cost
of donated drugs [11]. We ignored cost data from the first round of
MDA in Burkina Faso, because of possible bias due to extra start-
up costs. The value of personnel time devoted to MDA in Burkina
Faso was based on data collected from Ministry of Health
personnel in the national LF program plus regional and district
health personnel who participated in the program. [9]. Data from
Ghana, from the same publication, were not considered, because
they were based on a lower number of data points.
We used a series of calculation steps to estimate the relative cost
in 2009 for treating a population with 100,000 eligible persons in
both India and West Africa, while correcting for salary or per diem
changes, inflation since the original cost study, and potential
programmatic changes (see Table 2 for details).
Step 2. Estimate the average cost per year and treatment
round for semiannual treatment. Firstly, the cost of treating
a population with 100,000 eligibles once (the result of step 1 above)
was split up by program activity (sensitization, drug distribution,
etc.) and cost item (personnel, supplies, transportation, equipment
and facilities). Information about this for India was available from
Krishnamoorthy et al [9]. For West Africa, we used the
information presented by Goldman et al [11], supplemented by
more detailed tables than included in the previous publication.
The relative cost of some activities and cost items were increased,
in line with step 9 of Table 2. Also, in calculating the 2009 drug
costs, we used current prices for DEC purchased by the Indian
government and current donor valuations for ivermectin and
albendazole. The list of activities and cost items for India and West
Africa was slightly different, because of differences in program
organization and study design choices made by the authors.
Secondly, we made assumptions on the relative increase in cost
per year by activity, if MDA were to be provided twice instead of
once per year. We assumed that no extra efforts and costs would
be required for planning/administration, training, and surveil-
lance/laboratory activities. Costs for enumeration of populations
at risk, drug distribution, and for supervision and adverse reaction
monitoring would double, with the exception that no extra capital
expenses (for equipment and facilities) would be incurred.
Sensitization (social mobilization) would also be repeated, and
we assumed that the associated cost of supplies would double
(items such as posters, radio and newspaper advertisements), but
that costs for personnel and transportation involved in social
mobilization would increase by only 35%; again no extra costs for
capital expenses are assumed. Our assumptions, regarding which
activities are repeated in semiannual MDA programs, were based
in part on costing studies performed for soil-transmitted helminth
control programs [27,28]. Additional information came from the
observed choices of program managers in Burkina Faso, during a
2010 budgeting exercise for twice annual distributions for
onchocerciasis in highly endemic districts (A. Goldman, unpub-
lished observations). The average cost per round for semiannual
MDA (overall, or by activity and cost item) was then calculated as
one half of the cost per year.
Step 3. Estimate the cumulative cost of MDA programs
with annual or semiannual MDA, considering the total
required program duration and discounting. Overall pro-
gram and economic costs were calculated, taking account of the
total required program duration as predicted by LYMFASIM.
The overall costs were discounted at a rate of 3% to adjust for a
preference to delay cost to the future (some further explanation
about discounting can be found in the supporting information text
S1). Separate calculations were made including and excluding the
cost of donated drugs. We assumed that drugs would be purchased
or provided for all people eligible for MDA and that any unused
drugs are wasted: i.e. they are not used in later MDA rounds,
because they were either distributed and not consumed or they
were lost, damaged, or expired [9,26,29].
Sensitivity analysis
We studied the extent to which key assumptions affect
conclusions regarding the relative cost of the two MDA schedules
(once or twice yearly MDA) in a univariate sensitivity analysis. On
the cost side, we assessed the effect of changing the discount rate to
0% or 6% instead of 3%, the effect of including the cost of donated
drugs, and we considered the scenario where drugs are only
bought for people who are actually treated instead of for all
eligibles (with the idea that any remaining drugs would be stored
and used in a later round). These factors do not influence the
number of rounds required, but they may affect the total costs of
annual and semiannual treatment programs and influence policy
decisions.
With respect to the simulations, we examined the impact of
changing assumptions regarding the efficacy of drugs on adult
worms. This may affect the total number of treatment rounds (and
total costs) required for LF elimination programs with annual or
semiannual MDA. The fraction of worms assumed to be killed or
permanently sterilized after each treatment was varied with low,
medium (baseline) and high values (50%, 65%, and 80% for
DEC+ALB, and 20%, 35% and 50% for IVM+ALB). Further, we
studied the impact of including variability in this parameter, so
that the fraction of worms killed or sterilized varies randomly
between individuals in each treatment cycle and within individuals
in different treatment cycles. The variation is described by a beta
Semiannual MDA to Eliminate LF: Impact and Costs
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distribution with the mean equal to the baseline fraction of worms
killed/sterilized and standard deviation equal to 0.3.
Results
Illustrative examples of simulation results
Figure 1 shows an example of model-predicted trends in mf
prevalence. The presented trends are for a West African area with
a pre-control mf prevalence of 20%. Six rounds of annual MDA
with IVM+ALB were provided starting at time 0. Coverage was
70% and drug efficacy was quantified according to our baseline
assumptions. The figure displays the trend of 25 runs that were all
conducted with the same input assumptions. Variation in the
outcomes is due to stochasticity. In this example, 1 out of 25 runs
showed recrudescence after stopping MDA; one other run seemed
to be moving to elimination, but this was not yet achieved. The
probability of elimination in this case was 23/25 (92%).
Figure 2 illustrates how the model-predicted probability of LF
elimination increases with the number of MDA rounds provided.
Results are shown for the India and West Africa model variants,
for annual and semiannual MDA, and for different coverage
levels.
Estimated cost per treatment round
Table 3 shows the expected costs per treatment round by
activity and cost item for annual and semiannual MDA in both
regions. Providing semiannual instead of annual MDA reduces the
cost per MDA round. This cost reduction is 11% for India and
18% for West Africa, if costs of donated drugs are excluded from
the analysis. The cost reduction is smaller if donated drug costs are
included (7% for India and only 1% for West Africa).
Total program cost taking account of predicted duration
of MDA
Table 4 shows the number of treatment rounds for achieving a
99% probability of elimination, under our baseline assumptions.
This number is highly dependent on treatment coverage and pre-
treatment mf prevalence rates, but it does not depend much on the
frequency of treatment (annual or semiannual). In most circum-
stances, therefore, the total duration of semiannual MDA is about
half of that for annual MDA. In very unfavorable circumstances
(areas with high baseline infection rates and very low MDA
coverage), one extra MDA round may be required to reach
elimination with semiannual MDA.
The total costs of MDA programs depend on the cost per
round, the required number of MDA rounds, and thereby also on
local circumstances and coverage rates. Table 4 shows estimated
total costs for LF elimination programs, assuming an annual
discount rate of 3% for future costs. In this analysis, which does
not count the cost of any donated drugs, projected costs of
semiannual MDA are almost always lower than costs of annual
MDA. In West Africa, this is even true when semiannual MDA
requires one more MDA round, because of the large reduction in
cost per round. In the single India scenario where semiannual
MDA required one more round than annual MDA, the projected
total program costs were comparable for annual and semiannual
MDA.
Sensitivity analysis
Table 5 and Table 6 summarize the results of the sensitivity
analyses for India and West Africa. The tables show the ratio of
total program costs for semiannual MDA over annual MDA under
Table 2. Calculation steps for estimating the cost of a single mass drug administration (MDA) round.
India Burkina Faso Reference
1. Total cost of MDA as reported, including the cost of drugs (US$, base yeara value) 70,412 [23]
2. Total cost of MDA as reported, excluding costs of drugs (US$, base year value) 110,000 [11]
3. Population at risk 2,269,477 2,613,000 [11,23]
4. Percentage of the population at risk that is eligible for treatment (%) 90 85
5. Cost per 100,000 eligibles, incl. the cost of drugs (US$, base year value) 3,447b n.a.
6. Cost per 100,000 eligibles, excl. the cost of drugs (US$, base year value) 808c 4,953
7. As 6), (US$, comparative value in 2009) 1,139d 9,299d
8. As 7) after correction for recent programmatic and salary changes, excl. cost of drugs 2,710e 12,378f
9. as 8), incl. the cost of any purchased drugs 3,634g n.a.
10. as 9), incl. the cost of purchased and donated drugs 5,834h 434,578i
The table displays the source data and describes all steps that were taken to estimate the cost of a single MDA round per 100,000 eligibles.
n.a. = not applicable.
aThe term base year refers to the year in which cost were originally measured (1996 for India, 2002 for West Africa).
bCalculated from 1), 3) and 4), assuming that drugs (50 mg DEC tablets) were purchased for all eligible persons.
cFor India: cost of DEC (50-mg tablets; 5.2 tablets p.p. on average; 0.026 US$ p.p. on average) were subtracted.
dCorrection for inflation, using the annual deflators as published by the World Bank [24], i.e. the rate of price change in the economy as a whole. The amount under 6)
was first converted back to local currency using the base year conversion rate. Then we applied the correction for inflation between the base year and 2009. The new
amount was reconverted into US dollars using the 2009 conversion rate. Average annual inflation in India was about 5% between 1996 and 2009. The average annual
inflation between 2002 and 2009 in Burkina Faso was 9%.
eWe assume that sensitization efforts in India are intensified to achieve higher coverage, as studied elsewhere [25,26]. Associated extra costs (for personnel and supplies)
would be 0.009 US $ per person in 2002, or 0.015 US$ per eligible if adjusted to 2009 values.
fVolunteer remuneration has changed. In 2002, volunteers were paid for 2 days of training only, not distribution. By 2010 Burkina volunteers were remunerated for
about 2.5 days training and 7 days distribution; the daily rate remained the same. [sources: [11] and personal communications from program directors in Burkina Faso in
2011].
gIn India, DEC has to be purchased by the government, at 0.00924 US% p.p. on average (for 100 mg tablets, 2.75 tablets p.p. on average).
hDonated drug: albendazole (0.022 US$ p.p.).
iDonated drugs: albendazole (0.022 US$ p.p.) and ivermectin (4.2 US$ p.p. on average).
doi:10.1371/journal.pntd.0001984.t002
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varied assumptions. This ratio shows which approach is less
expensive (with values ,1 indicating that semiannual MDA is
cheaper and vice versa), and it provides an indication of the
relative cost difference. Changing the discount rate (0% or 6%)
had little impact on the projected total costs of semiannual and
annual MDA programs and their ratios. Its effect increased with
the duration of MDA, and a higher discount rate tends to favor the
slower annual MDA programs. But the total program cost of
semiannual MDA was lower or comparable to the cost of annual
MDA in all scenarios.
Including the costs of donated drugs changed the outcome of
the cost analysis significantly. The costs per treatment round
increased by a large amount (by an amount that was the same for
annual and semiannual treatment), and the relative difference was
reduced. While semiannual MDA remained cheaper in most
Indian scenarios, it became slightly more expensive in the West
African scenarios. The highest increase (17%) was seen in the West
African scenario with the highest endemicity (pre-control mf
prevalence of 27%), because here semiannual MDA would require
one more round than annual MDA. Whether drugs are purchased
for all eligibles in every round or for the percentage of people
treated only (assuming that previously unused drugs were not
wasted/expired), hardly affected the ratio of total program cost of
semiannual over annual MDA.
Model assumptions about the percentages of adult worms killed
(or permanently sterilized) by a single treatment affected the total
number of treatment rounds needed to achieve elimination and
therefore the estimated total program costs. However, this did not
have a major impact on ratios of total program cost for semiannual
vs. annual MDA programs (Table 6). Adding random variation in
the percentage of adult worms killed (or permanently sterilized)
sometimes led to an extra treatment round in either annual or
semiannual MDA, but nevertheless semiannual MDA was still
favored in this analysis.
Discussion
Our simulations and cost calculations suggest that semiannual
MDA will achieve LF elimination in about half of the time that
would be required with annual MDA. Estimated total program
costs were strongly driven by the required number of treatment
rounds, and this in turn depended on pre-treatment endemicity
levels and MDA coverage rates. However, total program costs for
endemic countries (i.e. excluding the cost of donated drugs) were
always lower for the semiannual MDA program or comparable.
Cost projections
Cost calculations were based on observed data from 1996 and
2002 [9,11], which were then adjusted to reflect current day
practices and prices. The absolute cost estimates are subject to
various assumptions. For the current purpose, though, the main
interest is in the relative cost of semiannual vs. annual MDA,
which is much less dependent on the assumptions. Key
assumptions in the cost projections did not affect the conclusion
that the cost of LF elimination with semiannual MDA is lower
than or similar to the cost of programs with annual MDA. A high
Figure 1. Simulated trends in mf prevalence (%) after mass drug administration. The presented trends are for an African setting with pre-
control mf prevalence around 20%, where 6 rounds of annual mass drug administration with IVM+ALB were provided starting at time 0. Coverage
was 70% and drug efficacy was quantified according to our baseline assumptions. The figure displays the trend of 25 runs, simulated by LYMFASIM,
all with the same input assumptions. Variation in the outcomes is due to stochasticity.
doi:10.1371/journal.pntd.0001984.g001
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discount rate (reflecting a strong preference to delay cost to the
future) favors annual MDA programs, in which the expenses are
spread over a longer period and postponed further into the future.
However, the efficiency gains of semiannual MDA mostly
compensate for this. If the high costs of donated drugs are
included in the cost estimates, the relative difference in cost per
round diminishes and becomes negligible in West Africa. In West
Africa, therefore, the efficiency gain no longer compensates for the
effect of discounting or the need for an extra treatment round in
semiannual MDA. But this situation only occurs when many
MDA rounds are required because of unfavorable transmission
conditions (as in our high endemic West African scenario). Slightly
increased program costs may be justified in such situations,
because here the positive impact of increasing MDA frequency on
total program duration is very strong. We did not test the impact
of future inflation with different annual inflation rates, but this
would work in favor of shorter duration semiannual MDA
programs, and it would tend to strengthen our conclusions.
Model predictions
Estimates of the required duration of MDA in different settings
were obtained by computer simulation, because empirical
evidence from LF elimination programs is still limited. Many
countries have made great strides, and some have stopped MDA,
but no country that had ongoing transmission of LF in 2000 has
been verified to have interrupted transmission of the infection
using MDA [4]. Modeling is a powerful tool for decision making in
infectious disease control [30], but predictions are subject to
uncertainty [31]. An important uncertainty in our study concerns
the efficacy of drugs. The sensitivity analysis showed that more
treatment rounds would be required if the employed drugs are less
effective than assumed and vice versa, while adding random
variability in the percentage of worms killed by treatment did not
influence the predicted outcomes. In any case, these assumptions
equally affected predictions for semiannual and annual MDA
programs and did not significantly affect the relative cost
difference between the two strategies.
Confirmation from field studies
Field studies are needed to confirm projected cost reductions
that can be achieved with semiannual MDA in both regions and to
assess any indirect effects that might affect the relative efficiency of
annual vs. semiannual MDA. For example, the likelihood that
unused medication is stored and used in subsequent rounds may
be higher in semiannual than in annual MDA programs. Also, it is
possible that increased treatment frequency will increase coverage
rates (e.g. due to higher population awareness) and reduce
systematic non-compliance (e.g. due to the fact that MDA does
not always take place in the same season). Such changes could
reduce the number of MDA rounds needed for elimination and
Figure 2. Probability of elimination in relation to the duration of mass drug administration. Panel A shows the results for an Indian
setting with a pre-control mf prevalence of about 11.5%, for annual and semiannual mass drug administration and for different coverage levels
(percentage of the total population that is treated per round). Similarly, panel B shows the results for an African setting with a pre-control mf
prevalence of about 20%. The indicated mf prevalence levels are for diagnosis with 60 mL night blood smears.
doi:10.1371/journal.pntd.0001984.g002
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further increase the efficiency of semiannual vs. annual MDA
programs. But the opposite could also occur if insufficient effort is
made to maintain high coverage rates.
Generalizability
The efficiency gain in cost per treatment round achieved by
shifting from annual to semiannual MDA was somewhat different
for India and West Africa. This reflects differences in program
organization and costing structure in the two regions [9,11]. For
example, the West African cost estimates included central
administrative costs, laboratory costs, and adverse reaction
monitoring, while these costs were not counted in the estimates
for India. In general, the efficiency gain achieved is dependent on
strategic choices (e.g. on activities to repeat and available budgets),
health systems, program organization, and the local cost of
different inputs. Results could be somewhat different in other
settings. In the supporting information text S1, we show how the
relative difference in total program costs depends on the relative
difference in cost per treatment round, the required number of
treatment rounds and applied discount rate.
The duration of MDA varies between regions because of
differences in exposure patterns to mosquitoes, characteristics of
the vector, timing of MDA, immigration of people, etc. Simulation
results are therefore not directly generalizable to other areas, but
this is not pertinent to the comparison of annual and semiannual
MDA durations. This becomes clear when one compares results
projected in this study for LF elimination programs in India and
West Africa; although there are important differences between
these models that result in very different estimates for the number
of MDA rounds needed for elimination (generally higher in
Africa), the basic conclusion that doubling MDA frequency halves
the required duration of LF elimination programs and reduces
total program costs is valid for both of these regions and it should
also apply to other regions.
Implications for LF elimination programs
Besides the total program costs, there are other important
factors to consider in deciding whether MDA frequency should be
increased. Increasing treatment frequency leads to a faster decline
in the incidence of LF infection. This should increase the
likelihood of achieving LF elimination by the target year of
2020, which is very relevant for countries that have not yet started
their MDA programs. Incidence of clinical manifestations will also
decline faster, which results in larger population health gain in
terms of the total number of DALYs averted and results in
increased productivity. Quantification of these extra benefits was
beyond the purpose of this study. Increasing the treatment
frequency and reducing program duration may also be beneficial
for other reasons. E.g., shorter programs may be more politically
attractive to health officials, and they would also be expected to
have reduced risks of interruption due to natural disasters, political
instability, or wars. Shorter programs may also reduce the risk of
emergence of resistance to anthelmintics during LF elimination
programs. Since albendazole and ivermectin also affect other
Table 4. Number of treatment rounds required for elimination and total costs of mass drug administration programs.
# rounds required Program costs (USD61000)
Setting
Pre-treatment mf
prevalence Coverage (%) Annual Semiannual Annual Semiannual
India 7.7% 55 3 3 10.6 9.6
70 2 2 7.2 6.5
85 2 2 7.2 6.5
11.5% 55 5 5 17.1 15.8
70 3 3 10.6 9.6
85 2 2 7.2 6.5
15% 55 9 10 29.1 30.4
70 5 5 17.1 15.8
85 3 3 10.6 9.6
West Africa 12.5% 55 7 7 79.4 68.2
70 5 5 58.4 49.4
85 4 4 47.4 39.9
20% 55 11 12 118.0 112.9
70 7 7 79.4 68.2
85 6 6 69.1 59.0
27.5% 55 .20a .20a n.a. n.a.
70 13 14 135.6 129.9
85 9 9 99.3 86.5
Results are shown for Indian and West African scenarios, for varying pre-control mf prevalence levels (based on diagnosis with 60 mL blood smears), for annual and
semiannual mass drug administration with varying coverage levels. Coverage is defined as the percentage treated out of the total population (including non-eligibles).
Total program costs are estimated for a total population of 100,000 eligible persons, based on the estimated total cost per treatment round as presented in Table 3. The
costs of donated drugs are excluded (albendazole for India, ivermectin and albendazole for West Africa), but costs of any drugs that have to be purchased by the
government are included (DEC for India). The discount rate for future costs was assumed to be 3%. Costs are in 2009 US$61000.
Abbrevations: n.a. = not available.
aSituation unfavorable for elimination.
doi:10.1371/journal.pntd.0001984.t004
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diseases than LF, increasing the treatment frequency would
increase their impact on diseases like soil-transmitted helminths
and other NTD’s – albeit for a shorter period.
Potential barriers for increasing the frequency of MDA are the
increased cost per year and practical difficulties that may be
associated with semiannual MDA. Increased annual drug
requirements may exceed supplies of donated drugs. Also, more
frequent MDA might overwhelm countries’ capacities for deliv-
ering MDA to endemic populations, in view of already heavily
burdened health systems and many competing health priorities
[32]. Semiannual MDA may not be feasible in all areas due to
weather, seasonal migration of populations, or logistical consider-
ations. Other factors may play a role when LF elimination is
integrated with programs for control of other neglected tropical
diseases (NTDs). That is to say, how would accelerated LF
elimination affect control programs for other NTDs?
Poor-performing programs, with very low treatment coverage,
require relatively many treatment rounds. Increasing the treat-
ment frequency from annually to semiannually would reduce the
total program duration by about half, but not the number of
treatment rounds. However, investments or strategies that increase
coverage rates will improve results of annual or semiannual MDA,
thereby reducing the number of treatment rounds required and
the total costs (see Table 4).
Conclusion
In summary, computer simulations suggest that the frequency of
MDA – annual vs semiannual – does not strongly influence the
total number of treatment rounds required to achieve LF
elimination. The costs per year are higher with semiannual
MDA, but total program costs (excluding donated drugs) are
projected to be lower or about the same when semiannual MDA is
used. The few situations where the total program costs of
semiannual MDA are slightly higher are also challenging situations
for LF elimination where semiannual MDA may improve the odds
of success. Therefore, we expect semiannual MDA to be superior
to annual MDA in most endemic settings. Considering the GPELF
goal of LF elimination by 2020, semiannual MDA should be
considered as a means of accelerating LF elimination in areas
where it can be implemented.
Supporting Information
Text S1 Shifting from annual to semiannual MDA in LF
elimination programs: relative efficiency gains, the
number of treatment rounds required, and the discount
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